HAE - CureVac downgraded following COVID vaccine data Regeneron COVID cocktail a boon and more in analyst action

Christian Kaspar-Bartke/Getty Images News BofA downgrades CureVac following disappointing COVID vaccine data Following the release yesterday of disappointing data in a phase 2b/3 trial of its COVID-19 vaccine, BofA Securities has downgraded shares of CureVac (CVAC) from buy to neutral and cut the price target from $110 to $50. (~47% downside). Analyst Geoff Meacham says he is removing the vaccine from his model, though he does see potential from the company's second-generation vaccine, CV2CoV. "We've long been more positive on CureVac’s mRNA platform to treat non-COVID-19 infectious diseases and different tumor types (i.e. melanoma), so we continue to see upside potential from further derisking of these programs," Meacham writes. However, he is lowering the likelihood of success for other infectious disease programs from 35% to 25%. Regeneron maintained a buy on REGN-COV data Benchmark is reiterated its buy recommendation on Regeneron (REGN) based on study results released yesterday on the

For further details see:

CureVac downgraded following COVID vaccine data, Regeneron COVID cocktail a boon, and more in analyst action